Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors

Chronic infection and associated inflammation have long been suspected to promote human carcinogenesis. Recently, certain gut bacteria, including some in the Fusobacterium genus, have been implicated in playing a role in human colorectal cancer development. However, the Fusobacterium species and subspecies involved and their oncogenic mechanisms remain to be determined. We sought to identify the specific Fusobacterium spp. and ssp. in clinical colorectal cancer specimens by targeted sequencing of Fusobacterium 16S ribosomal RNA gene. Five Fusobacterium spp. were identified in clinical colorectal cancer specimens. Additional analyses confirmed that Fusobacterium nucleatum ssp. animalis was the most prevalent F. nucleatum subspecies in human colorectal cancers. We also assessed inflammatory cytokines in colorectal cancer specimens using immunoassays and found that expression of the cytokines IL17A and TNFα was markedly increased but IL21 decreased in the colorectal tumors. Furthermore, the chemokine (C-C motif) ligand 20 was differentially expressed in colorectal tumors at all stages. In in vitro co-culture assays, F. nucleatum ssp. animalis induced CCL20 protein expression in colorectal cancer cells and monocytes. It also stimulated the monocyte/macrophage activation and migration. Our observations suggested that infection with F. nucleatum ssp. animalis in colorectal tissue could induce inflammatory response and promote colorectal cancer development. Further studies are warranted to determine if F. nucleatum ssp. animalis could be a novel target for colorectal cancer prevention and treatment. Cancer Prev Res; 10(7); 398–409. ©2017 AACR.

[1]  Jens Roat Kultima,et al.  Potential of fecal microbiota for early‐stage detection of colorectal cancer , 2014 .

[2]  H. Tajiri,et al.  Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. , 2009, Journal of medical microbiology.

[3]  E. El-Omar,et al.  The Inflammatory Microenvironment in Colorectal Neoplasia , 2011, PloS one.

[4]  R. Sandler,et al.  Fusobacterium Is Associated with Colorectal Adenomas , 2013, PloS one.

[5]  T. Ohkusa,et al.  Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis , 2003, Gut.

[6]  E. Goldstein,et al.  16S-23S rDNA internal transcribed spacer sequences for analysis of the phylogenetic relationships among species of the genus Fusobacterium. , 2002, International journal of systematic and evolutionary microbiology.

[7]  Claudia Rubie,et al.  Involvement of Chemokine Receptor CCR6 in Colorectal Cancer Metastasis , 2006, Tumor Biology.

[8]  C. Huttenhower,et al.  Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. , 2015, JAMA oncology.

[9]  Dae-Soo Kim,et al.  Draft Genome Sequence of Fusobacterium nucleatum subsp. vincentii ChDC F8, Isolated from a Human Subgingival Plaque in the Republic of Korea , 2013, Genome Announcements.

[10]  H. Tjalsma,et al.  The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. , 2013, The Lancet. Infectious diseases.

[11]  Robert C. Edgar,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2001 .

[12]  Mingyang Song,et al.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis , 2015, Gut.

[13]  C. Sears,et al.  Microbiota and Immune Responses in Colon Cancer: More to Learn , 2014, Cancer journal.

[14]  N. Munshi,et al.  CCR6, the Sole Receptor for the Chemokine CCL20, Promotes Spontaneous Intestinal Tumorigenesis , 2014, PloS one.

[15]  D. Kerjaschki,et al.  Association between intraepithelial Escherichia coli and colorectal cancer. , 1998, Gastroenterology.

[16]  O. Yoshie,et al.  Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3alpha/CCL20 in mucosal epithelial cells through NF-kappaB [correction of NK-kappaB]. , 2001, International immunology.

[17]  W. Wade,et al.  Genotypic and phenotypic characterization of fusobacteria from Chinese and European patients with inflammatory periodontal diseases. , 2006, Systematic and applied microbiology.

[18]  A. Mira,et al.  Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers , 2015, Journal of Gastroenterology.

[19]  Hong Wang,et al.  CCR6 Is a Prognostic Marker for Overall Survival in Patients with Colorectal Cancer, and Its Overexpression Enhances Metastasis In Vivo , 2014, PloS one.

[20]  C. Roques,et al.  Fusobacterium nucleatum in periodontal health and disease. , 2011, Current issues in molecular biology.

[21]  J. Goedert,et al.  Human gut microbiome and risk for colorectal cancer. , 2013, Journal of the National Cancer Institute.

[22]  M. Meyerson,et al.  Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. , 2013, Cell host & microbe.

[23]  R. Genco,et al.  Interactions between Periodontal Bacteria and Human Oral Epithelial Cells: Fusobacterium nucleatum Adheres to and Invades Epithelial Cells , 2000, Infection and Immunity.

[24]  Cynthia L Sears,et al.  Microbes, microbiota, and colon cancer. , 2014, Cell host & microbe.

[25]  Robert C. Edgar,et al.  UPARSE: highly accurate OTU sequences from microbial amplicon reads , 2013, Nature Methods.

[26]  J. Farber,et al.  Human T Cells That Are Able to Produce IL-17 Express the Chemokine Receptor CCR61 , 2008, The Journal of Immunology.

[27]  Chen Dong,et al.  CCR6 Regulates the Migration of Inflammatory and Regulatory T Cells1 , 2008, The Journal of Immunology.

[28]  William A. Walters,et al.  Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms , 2012, The ISME Journal.

[29]  Y. Toiyama,et al.  Macrophage inflammatory protein‐3 alpha (MIP‐3a) Is a novel serum prognostic marker in patients with colorectal cancer , 2013, Journal of surgical oncology.

[30]  S. Moon,et al.  Application of rpoB and Zinc Protease Gene for Use in Molecular Discrimination of Fusobacterium nucleatum Subspecies , 2009, Journal of Clinical Microbiology.

[31]  A. Eley,et al.  Fusobacteria: new taxonomy and related diseases. , 1993, Journal of medical microbiology.

[32]  J. Farber,et al.  CCR6 Marks Regulatory T Cells as a Colon-Tropic, IL-10–Producing Phenotype , 2010, The Journal of Immunology.

[33]  O. Yoshie,et al.  Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3α/CCL20 in mucosal epithelial cells through NF-κB , 2001 .

[34]  P. Goldberg,et al.  Quantitative Profiling of Colorectal Cancer-Associated Bacteria Reveals Associations between Fusobacterium spp., Enterotoxigenic Bacteroides fragilis (ETBF) and Clinicopathological Features of Colorectal Cancer , 2015, PloS one.

[35]  Yan Peng,et al.  Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway , 2016, International journal of cancer.

[36]  A. McGuire,et al.  Complete genome sequences and analysis of the Fusobacterium nucleatum subspecies animalis 7-1 bacteriophage ɸFunu1 and ɸFunu2. , 2016, Anaerobe.

[37]  E. Allen-Vercoe,et al.  Fusobacterium nucleatum Infection of Colonic Cells Stimulates MUC2 Mucin and Tumor Necrosis Factor Alpha , 2011, Infection and Immunity.

[38]  A. Baqui,et al.  Antigen activation of THP-1 human monocytic cells after stimulation with lipopolysaccharide from oral microorganisms and granulocyte-macrophage colony-stimulating factor. , 1999, Journal of periodontal research.

[39]  E. Thiel,et al.  Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Hong Wang,et al.  Tumor-Associated Macrophages Recruit CCR6+ Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice , 2011, PloS one.

[41]  S. McColl,et al.  An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.

[42]  Richard A. Moore,et al.  Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. , 2012, Genome research.

[43]  G. Trinchieri Cancer and inflammation: an old intuition with rapidly evolving new concepts. , 2012, Annual review of immunology.

[44]  Young-Hyo Chang,et al.  Fusobacterium nucleatum subsp. fusiforme Gharbia and Shah 1992 is a Later Synonym of Fusobacterium nucleatum subsp. vincentii Dzink et al. 1990 , 2012, Current Microbiology.

[45]  Younis Hazari,et al.  Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut , 2016, Tumor Biology.

[46]  B. Ramakrishna,et al.  Real‐time polymerase chain reaction quantification of specific butyrate‐producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer , 2008, Journal of gastroenterology and hepatology.

[47]  Dae-Soo Kim,et al.  Draft Genome Sequence of Fusobacterium nucleatum subsp. animalis ChDC F324, Isolated from a Human Subgingival Plaque in the Republic of Korea , 2013, Genome Announcements.

[48]  L. Ellis,et al.  Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. , 2013, Cancer cell.

[49]  Emma Allen-Vercoe,et al.  Co-occurrence of anaerobic bacteria in colorectal carcinomas , 2013, Microbiome.

[50]  M. R. Rubinstein,et al.  Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. , 2013, Cell host & microbe.

[51]  Hiromu Suzuki,et al.  Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway , 2015, International journal of cancer.

[52]  Pelin Yilmaz,et al.  The SILVA ribosomal RNA gene database project: improved data processing and web-based tools , 2012, Nucleic Acids Res..

[53]  C. Sears Enterotoxigenic Bacteroides fragilis: a Rogue among Symbiotes , 2009, Clinical Microbiology Reviews.

[54]  E. Allen-Vercoe,et al.  Phenotypic and genotypic analyses of clinical Fusobacterium nucleatum and Fusobacterium periodonticum isolates from the human gut. , 2008, Anaerobe.

[55]  Tarah Lynch,et al.  Invasive potential of gut mucosa‐derived fusobacterium nucleatum positively correlates with IBD status of the host , 2011, Inflammatory bowel diseases.

[56]  J. Van Damme,et al.  The CC chemokine CCL20 and its receptor CCR6. , 2003, Cytokine & growth factor reviews.

[57]  B. Birren,et al.  Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. , 2012, Genome research.

[58]  P. Ghadjar,et al.  CCR6/CCL20 Chemokine Expression Profile in Distinct Colorectal Malignancies , 2013, Scandinavian journal of immunology.

[59]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.